Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P32926
UPID:
DSG3_HUMAN
Alternative names:
130 kDa pemphigus vulgaris antigen; Cadherin family member 6
Alternative UPACC:
P32926; A8K2V2
Background:
Desmoglein-3, also known as the 130 kDa pemphigus vulgaris antigen and Cadherin family member 6, plays a crucial role in cell-cell adhesion by being a component of intercellular desmosome junctions. It facilitates the interaction between plaque proteins and intermediate filaments, ensuring structural integrity in various tissues.
Therapeutic significance:
Desmoglein-3's involvement in the autosomal recessive disorder characterized by recurrent, suprabasal acantholytic blisters in the oral and laryngeal mucosa highlights its potential as a therapeutic target. Understanding the role of Desmoglein-3 could open doors to potential therapeutic strategies for treating blistering, acantholytic disorders of oral and laryngeal mucosa.